We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
The most recent trading session ended with Hims & Hers Health, Inc. (HIMS - Free Report) standing at $22.36, reflecting a -1.93% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.47% gain on the day. At the same time, the Dow added 0.79%, and the tech-heavy Nasdaq gained 0.28%.
The the stock of company has risen by 41.62% in the past month, leading the Medical sector's loss of 4.27% and the S&P 500's gain of 3.48%.
Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company's earnings report is set to go public on November 4, 2024. On that day, Hims & Hers Health, Inc. is projected to report earnings of $0.06 per share, which would represent year-over-year growth of 250%. Meanwhile, our latest consensus estimate is calling for revenue of $378.82 million, up 67.1% from the prior-year quarter.
HIMS's full-year Zacks Consensus Estimates are calling for earnings of $0.22 per share and revenue of $1.39 billion. These results would represent year-over-year changes of +300% and +59.79%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Hims & Hers Health, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Hims & Hers Health, Inc. is currently sporting a Zacks Rank of #4 (Sell).
Looking at its valuation, Hims & Hers Health, Inc. is holding a Forward P/E ratio of 105.97. This valuation marks a premium compared to its industry's average Forward P/E of 26.84.
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 74, finds itself in the top 30% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: What You Should Know
The most recent trading session ended with Hims & Hers Health, Inc. (HIMS - Free Report) standing at $22.36, reflecting a -1.93% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.47% gain on the day. At the same time, the Dow added 0.79%, and the tech-heavy Nasdaq gained 0.28%.
The the stock of company has risen by 41.62% in the past month, leading the Medical sector's loss of 4.27% and the S&P 500's gain of 3.48%.
Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company's earnings report is set to go public on November 4, 2024. On that day, Hims & Hers Health, Inc. is projected to report earnings of $0.06 per share, which would represent year-over-year growth of 250%. Meanwhile, our latest consensus estimate is calling for revenue of $378.82 million, up 67.1% from the prior-year quarter.
HIMS's full-year Zacks Consensus Estimates are calling for earnings of $0.22 per share and revenue of $1.39 billion. These results would represent year-over-year changes of +300% and +59.79%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Hims & Hers Health, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Hims & Hers Health, Inc. is currently sporting a Zacks Rank of #4 (Sell).
Looking at its valuation, Hims & Hers Health, Inc. is holding a Forward P/E ratio of 105.97. This valuation marks a premium compared to its industry's average Forward P/E of 26.84.
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 74, finds itself in the top 30% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.